stoxline Quote Chart Rank Option Currency Glossary
BioMarin Pharmaceutical Inc. (BMRN)
92.94  -2 (-2.11%)    12-08 16:00
Open: 94.27
High: 94.325
Volume: 1,782,857
Pre. Close: 94.94
Low: 92.36
Market Cap: 17,507(M)
Technical analysis
2023-12-08 4:42:00 PM
Short term     
Mid term     
Targets 6-month :  111.43 1-year :  130.16
Resists First :  95.41 Second :  111.43
Pivot price 90.62
Supports First :  83.53 Second :  76.19
MAs MA(5) :  94.01 MA(20) :  89.29
MA(100) :  88 MA(250) :  94.27
MACD MACD :  2.4 Signal :  1.9
%K %D K(14,3) :  86.3 D(3) :  89.8
RSI RSI(14): 62.4
52-week High :  117.76 Low :  76.01
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ BMRN ] has closed below upper band by 28.9%. Bollinger Bands are 52.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 94.44 - 94.93 94.93 - 95.36
Low: 91.18 - 91.74 91.74 - 92.22
Close: 92.01 - 92.97 92.97 - 93.79
Company Description

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.

Headline News

Tue, 28 Nov 2023
BioMarin Announces Agreement with German Health Insurance Fund on Reimbursement Amount for ROCTAVIAN ... - PR Newswire

Tue, 28 Nov 2023
BioMarin prices hemophilia gene therapy at nearly 29000 euros per vial in Germany - Reuters

Tue, 07 Nov 2023
Exclusive: Activist investor Elliott targets drugmaker BioMarin -sources - Reuters

Thu, 02 Nov 2023
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q3 2023 Earnings Call Transcript - Yahoo Finance

Thu, 02 Nov 2023
The Biomarin Pharmaceutical Inc (BMRN) Company: A Short SWOT Analysis - Yahoo Finance

Wed, 01 Nov 2023
BioMarin Announces Retirement of Jean-Jacques Bienaimé; Appoints Alexander Hardy President and Chief Executive ... - PR Newswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 188 (M)
Shares Float 187 (M)
Held by Insiders 0.4 (%)
Held by Institutions 97.7 (%)
Shares Short 3,080 (K)
Shares Short P.Month 7,030 (K)
Stock Financials
EPS 0.76
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 26
Profit Margin 6.3 %
Operating Margin 4.4 %
Return on Assets (ttm) 1.1 %
Return on Equity (ttm) 3.1 %
Qtrly Rev. Growth 15 %
Gross Profit (p.s.) 8.54
Sales Per Share 12.26
EBITDA (p.s.) 1.17
Qtrly Earnings Growth 0 %
Operating Cash Flow 139 (M)
Levered Free Cash Flow -12 (M)
Stock Valuations
PE Ratio 120.7
PEG Ratio 2.1
Price to Book value 3.57
Price to Sales 7.57
Price to Cash Flow 126.35
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android